Kennedy Capital Management LLC Has $2.49 Million Position in Insmed Incorporated (NASDAQ:INSM)

Kennedy Capital Management LLC grew its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 197.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 36,058 shares of the biopharmaceutical company's stock after purchasing an additional 23,940 shares during the period. Kennedy Capital Management LLC's holdings in Insmed were worth $2,489,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in INSM. Steward Partners Investment Advisory LLC increased its stake in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC grew its stake in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management acquired a new stake in shares of Insmed during the fourth quarter valued at about $47,000. Smartleaf Asset Management LLC lifted its stake in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 411 shares in the last quarter. Finally, Venturi Wealth Management LLC purchased a new position in Insmed in the fourth quarter valued at about $86,000.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 6,830 shares of Insmed stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,412,107.84. The trade was a 2.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 28,390 shares of the stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total value of $2,296,751.00. Following the sale, the chief financial officer now owns 155,506 shares of the company's stock, valued at $12,580,435.40. This trade represents a 15.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 471,797 shares of company stock valued at $37,621,239 over the last 90 days. 3.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

INSM has been the subject of several research analyst reports. Wells Fargo & Company increased their target price on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. UBS Group raised their price objective on shares of Insmed from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Bank of America increased their price target on shares of Insmed from $92.00 to $96.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a report on Wednesday, February 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Stock Performance

Shares of INSM stock traded up $2.33 during trading hours on Friday, reaching $72.53. The stock had a trading volume of 1,500,949 shares, compared to its average volume of 2,273,347. The firm has a market capitalization of $13.19 billion, a PE ratio of -12.97 and a beta of 1.07. The firm has a 50-day simple moving average of $75.49 and a 200-day simple moving average of $73.59. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. As a group, equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.